Literature DB >> 7636210

Characterization of latent TGF-beta activation by murine peritoneal macrophages.

I Nunes1, R L Shapiro, D B Rifkin.   

Abstract

Transforming growth factor-beta (TGF-beta) is secreted by most cells as a biologically inactive complex, called the large latent TGF-beta complex. The complex is comprised of latent TGF-beta binding protein (LTBP) and latent TGF-beta, which is mature TGF-beta associated noncovalently with its amino-terminal propeptides. LTBP is disulfide-linked to the amino-terminal propeptide of latent TGF-beta. Active TGF-beta is generated by release of TGF-beta from the complex. Generation of active TGF-beta by macrophages has been reported, but the activation mechanism has not been described. Latent TGF-beta activation by macrophages was characterized using serum-free cultures of resident and thioglycollate-elicited murine peritoneal macrophages that were either unstimulated or LPS-stimulated in vitro. Serum-free conditioned medium was assayed for TGF-beta using a quantitative luciferase-based bioassay. LPS-stimulated thioglycollate-elicited macrophages activated endogenous latent TGF-beta, whereas non-LPS-stimulated thioglycollate-elicited and resident macrophages generated undetectable levels of TGF-beta. Latent TGF-beta activation required plasmin and urokinase (uPA), uPA binding to the uPA receptor, interaction with the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor, tissue type II transglutaminase, and LTBP. A time-course analysis of latent TGF-beta activation revealed that maximal TGF-beta was generated after 24 h (25 +/- 5 pg/ml). TGF-beta formed within the initial 24 h modulated the plasminogen activator system by down-regulating uPA, suggesting that TGF-beta temporally modulated its own formation by regulating cell-associated uPA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636210

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation.

Authors:  Mai-Lan N Huynh; Valerie A Fadok; Peter M Henson
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  Invasive candidiasis stimulates hepatocyte and monocyte production of active transforming growth factor beta.

Authors:  J J Letterio; T Lehrnbecher; G Pollack; T J Walsh; S J Chanock
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 3.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

4.  Active transforming growth factor-beta in wound repair: determination using a new assay.

Authors:  L Yang; C X Qiu; A Ludlow; M W Ferguson; G Brunner
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

5.  MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily.

Authors:  M R Bootcov; A R Bauskin; S M Valenzuela; A G Moore; M Bansal; X Y He; H P Zhang; M Donnellan; S Mahler; K Pryor; B J Walsh; R C Nicholson; W D Fairlie; S B Por; J M Robbins; S N Breit
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

6.  Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta.

Authors:  S P Evanko; E W Raines; R Ross; L I Gold; T N Wight
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

Review 7.  The latent transforming growth factor beta binding protein (LTBP) family.

Authors:  R Oklü; R Hesketh
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

Review 8.  Cross-talk between nitric oxide and transforming growth factor-beta1 in malaria.

Authors:  Yoram Vodovotz; Ruben Zamora; Matthew J Lieber; Shirley Luckhart
Journal:  Curr Mol Med       Date:  2004-11       Impact factor: 2.222

9.  CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury.

Authors:  Franco R D'Alessio; Kenji Tsushima; Neil R Aggarwal; Erin E West; Matthew H Willett; Martin F Britos; Matthew R Pipeling; Roy G Brower; Rubin M Tuder; John F McDyer; Landon S King
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

10.  Prevention of experimental autoimmune encephalomyelitis in DA rats by grafting primary skin fibroblasts engineered to express transforming growth factor-beta1.

Authors:  T Zargarova; O Kulakova; V Prassolov; T Zharmukhamedova; V Tsyganova; V Turobov; D Ivanov; M Parfenov; M Sudomoina; Y Chernajovsky; O Favorova
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.